Connect with us

Politics

Marijuana Is A Big Issue In Next Month’s Elections

Published

on

In one month, voters in two states will decide, among other things, what kind of marijuana policies they want for their communities.

New Jersey and Virginia are the only two states holding gubernatorial elections this year, and the major party nominees in both races have all called for some measure of marijuana law reform.

Here’s a look at where the candidates stand…

NEW JERSEY

IN BRIEF: Democratic nominee Phil Murphy, a former U.S. ambassador to Germany, wants to make the Garden State the next to legalize, regulate and tax marijuana. Republican nominee, current Lieutenant Governor Kim Guadagno, opposes legalization but supports decriminalizing possession and expanding the state’s current medical cannabis law.

PHIL MURPHY – Democrat

Murphy included a call for legalization during his primary election victory speech in June.

“The criminalization of marijuana has only served to clog our courts and cloud people’s futures, so we will legalize marijuana,” he said. “And while there are financial benefits, this is overwhelmingly about doing what is right and just.” He also pledged in the speech to end mass incarceration and “eliminate prisons for profit.”

On his campaign website, Murphy pledges to “legalize marijuana so police can focus resources on violent crimes.”

In a gubernatorial candidates’ forum he said that while legalization will generate tax revenue, his primary reason for supporting the policy is “a social justice reason.” He also alleged that the administration of current Gov. Chris Christie (R) has “gummed up” the state’s medical cannabis program.

In a general election debate, he said that legalizing cannabis should be part of “comprehensive criminal justice reform” and described ending prohibition as a “social justice” issue, citing his role as a national NAACP board member.

In another general election debate, Murphy said decriminalization isn’t enough because “the drug industry stays underground, run by the same people and it’s unregulated, so therefore minors in particular are exposed to that. But set aside the fact you don’t earn the tax revenue, which is also a reality, the fact is it remains the wild west.”

Murphy made his support for legalization clear during his primary election campaign, and often tweeted about the issue.

“I was never ‘hell no,’ but I’ve spent a lot of time on it. And I have, without question, come to a place where I wasn’t three and a half years ago,” Murphy said in a New York Times interview about his evolution on marijuana. “You can’t have that many young people of color doing time on stupid drug crimes.”

KIM GUADAGNO – Republican

During a primary debate this year, Guadagno made it clear that she opposes legalization but does support some cannabis reforms.

“I have personal experience about what exactly happens to somebody who drives while they’re high, which is why I would oppose legalization of marijuana,” she said, noting that her son went to college in Colorado. “Having said that, however, I completely agree that we should decriminalize it. Because no one should suffer because of the color of their skin or because of their social background or because they were picked up with a small quantity. What that quantity is is up for argument.”

On medical cannabis, Guadagno said the state should “streamline” access and “make it easier for people that have doctors’ notes to get it and we need to provide it to children that need it the most.”

But she said that full marijuana legalization would put the state at risk of federal interference.

In a gubernatorial candidates’ forum she said legalizing marijuana would “put a whole generation of children at risk” and that ending prohibition would give her 17-year-old son an “opportunity” to use cannabis.

During a general election debate, Guadagno said she is “wholly opposed” to ending prohibition, which she described as “legalizing drug dealers.” But she said decriminalization “would solve the social justice issue.” And she would “expand the medical marijuana program,” adding: “It’s onerous, it’s hard to work with, it’s not available to those it should be made available to.”

In another general election debate, she said she won’t legalize marijuana because she’s concerned about intoxicated driving and access to kids. “I don’t want our children, I don’t want our people to walk down the street and buy a pack of cigarettes and be drug dealers,” she said.

CONTEXT: Legislative leaders in New Jersey have indicated they are prepared to enact legalization as soon as a supportive governor is seated. Currently Gov. Chris Christie (R), who is term-limited and cannot run again, is one of the nation’s most prominent opponents of ending cannabis prohibition.

VIRGINIA

IN BRIEF: Democratic nominee, current Lieutenant Governor Ralph Northam, supports decriminalizing marijuana and expanding medical cannabis access. Republican nominee Ed Gillespie, a former Republican National Committee chairman, doesn’t support those outright changes but has said he supports policies that would reduce marijuana arrests as well as enacting a more limited expansion of the state’s current low-THC medical cannabis law.

RALPH NORTHAM – Democrat

Northam has made marijuana law reform a centerpiece of his campaign, often describing the issue in racial justice terms.

“We need to change sentencing laws that disproportionately hurt people of color. One of the best ways to do this is to decriminalize marijuana,” he wrote in a blog post early this year. “African Americans are 2.8 times more likely to be arrested for marijuana possession in Virginia. The Commonwealth spends more than $67 million on marijuana enforcement — money that could be better spent on rehabilitation.”

As a physician, Northam is “increasingly convinced by the data showing potential health benefits of marijuana, such as pain relief, drug-resistant epilepsy, and treatment for PTSD,” his campaign website says. “By decriminalizing it, our researchers can better study the plant so doctors can more effectively prescribe drugs made from it.”

The lieutenant governor also sent a letter to the Virginia State Crime Commission, which is currently conducting a review of the effects of potential marijuana decriminalization. “Virginia spends $67 million on marijuana enforcement – enough to open up another 13,000 pre-K spots for children,” Northam wrote. “African Americans are nearly 3 times as likely to get arrested for simple possession of marijuana and sentencing guidelines that include jail time can all too often begin a dangerous cycle of recidivism.”

During a debate, Notham mentioned that his father is a judge while making a point about the cost of enforcing marijuana laws.

Northam has tweeted about cannabis reform a number of times.

Northam says he “often” encounters patients who benefit from medical marijuana, and he released a campaign ad telling the story of a young constituent of his for whom he helped gain cannabis access.

Additionally, Northam supports federal cannabis rescheduling. “What would happen after that is marijuana would be reclassified and then we can look at medicinal uses,” he told HuffPost. “And the point I like to make to people is there are probably around 100 or more medicines we use routinely that come from plants. And so there are many potential uses for marijuana.”

He also backs allowing hemp cultivation. “A Northam administration will support new efforts to bring Virginia products to market, including industrial hemp processing,” his campaign website says. “Several of our key public institutions, including Virginia State University, Virginia Tech, University of Virginia and James Madison University, are conducting field research on industrial hemp [and] Virginia could explore workarounds to increase access to hemp for private growers. Additionally, at the federal level, Ralph supports the removal of industrial hemp from the Controlled Substances Act of 1970… As part of Ralph’s economic development plan, he will continue efforts to recruit an industrial hemp processor for when then federal law changes.”

ED GILLESPIE – Republican

At the start of the campaign Gillespie wasn’t on record in favor of any changes to marijuana laws. But Northam’s reform advocacy, and the response it has generated, has apparently influenced the Republican to look more seriously at the issue.

Last month Gillespie rolled out a criminal justice reform plan that includes a “Three Strikes and You’re In” policy that would allow people arrested for marijuana possession to avoid criminal charges until their third police encounter.

“This policy will reduce the number of Virginians who enter the criminal justice system and help to get treatment to more people,” Gillespie’s plan says. “Data show significant racial disparities in marijuana charges, this policy will help address them by providing opportunities to avoid entry into the criminal justice system and encouraging people to get help and reconsider their choices.”

Under the policy, cannabis would not be formally decriminalized.

Gillespie’s plan also calls for modest expansion’s to the state’s limited low-THC medical cannabis law.

“Research proves that Virginians can benefit from certain uses of marijuana to help the treatment, pain management, and healing of certain severe conditions. We owe our fellow Virginians every chance of treating and managing certain significant conditions such as cancer and epilepsy,” it says. “Ed supports appropriate, limited, tightly regulated use of marijuana for medicinal purposes based in science and on medical trials.”

State Sen. Jill Vogel, Gillespie’s lieutenant governor running mate, previously introduced legislation to add new qualifying medical conditions under the law. “Expanding safe, legal access to CBD oil and medical marijuana for seriously ill patients gives doctors another option and ensures patients aren’t forced to choose between receiving treatment and following the law,” Vogel said. “I’m proud to have taken the lead in introducing legislation in Virginia’s Senate helping expand safe, legal access for patients in need and look forward to working with my party as an advocate for this much-needed policy reform.”

In an earlier Facebook Live chat, Gillespie said, “I think there has been a growing case for tightly regulated, strictly regulated medicinal marijuana.”

Gillespie also supports allowing hemp cultivation. “Industrial hemp is a cash crop and can be found in a variety of products such as paper construction materials, food, personal care items, rope, canvas and nutritional supplements,” his campaign website says. “Ed will work with the federal government, General Assembly and licensing boards to explore industrial hemp production as an option for Virginians.”

As a Republican, Gillespie argues he is best positioned to push the federal government to modernize its approach to hemp. “Given the science and the data that we have at this point, I would be one who would be able to work with the Trump administration to be able to make the case for Virginia being one of the areas where we should be able to establish some practices and procedures for us to be able to have commercial development for industrial hemp,” he said.

CONTEXT: Virginia lawmakers considered but did not act on decriminalization legislation during the 2017 session. However, with the State Crime Commission conducting its study of the issue by the request of the Senate majority leader, its possible recommendation of removing marijuana’s criminal penalties would likely provide a significant boost to efforts to pass a bill.

Election day in both New Jersey and Virginia is Tuesday, November 7.

Photo courtesy of Democracy Chronicles.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Tom Angell is the editor of Marijuana Moment. A 20-year veteran in the cannabis law reform movement, he covers the policy and politics of marijuana. Separately, he founded the nonprofit Marijuana Majority. Previously he reported for Marijuana.com and MassRoots, and handled media relations and campaigns for Law Enforcement Against Prohibition and Students for Sensible Drug Policy. (Organization citations are for identification only and do not constitute an endorsement or partnership.)

Politics

Congress To Vote On Marijuana, Psychedelics And CBD Amendments This Week Following Committee Action

Published

on

A key House committee on Monday cleared a series of cannabis and psychedelics-related amendments for floor votes as part of large-scale spending legislation. That floor action could happen as soon as Tuesday.

However, the panel also blocked two measures on housing protections for cannabis consumers that legalization supporters hoped to see advance.

One of the most notable amendments the House Rules Committee allowed to move forward for possible attachment to appropriations legislation would remove a rider that advocates say has restricted federal funds for research into Schedule I drugs, including psychedelics such as psilocybin, MDMA and ibogaine.

The reform measure is being sponsored by Rep. Alexandria Ocasio-Cortez (D-NY), and it targets 1990s-era provision that’s long been part of spending legislation for the Department of Health and Human Services (HHS). The congresswoman attempted to eliminate the language via an amendment in 2019 only to have it defeated by Republicans as well as a majority of her party. But it’s far from the only measure being proposed this appropriations season when it comes to drug policy matters.

Some are being backed by reform advocates, while others have received sharp criticism.

One pro-reform amendment that’s advancing would encourage the Food and Drug Administration (FDA) to approve rules allowing CBD as a dietary supplement and food ingredient.

On the other side, there is a proposal from Rep. Debbie Lesko (R-AZ) to the HHS appropriations bill to eliminate a rider that’s currently in the bill that “allows federal funding to go to institutions of higher education that are conducting research on marijuana.”

The reason this measure has generated particular pushback is because research into cannabis is an overwhelmingly bipartisan issue, and top federal drug officials have repeatedly urged Congress to support policies that make it easier to study the risks and benefits of the plant. What’s more, Lesko represents a state with adult-use legalization on the books.

Activists are disappointed that two marijuana reform measures from Rep. Eleanor Holmes Norton (D-DC) are being blocked from floor consideration. Her proposals—which were aimed at appropriations legislation for the Department of Housing and Urban Development (HUD)—would have made it so marijuana possession or consumption could not be used as the sole basis for denying people access to public housing. One Norton amendment was narrowly focused on medical cannabis while a second measure would have covered all marijuana use that’s legal under state laws.

“It’s disappointing that those who rely on public support for housing will continue to be discriminated against for their state-legal choices,” NORML Political Director Justin Strekal told Marijuana Moment.

Advocates were surprised that the Rules Committee, chaired by marijuana reform supporter Rep. James McGovern (D-MA), sought to prevent a floor vote on the Norton cannabis amendments.

A committee spokesperson told Marijuana Moment that the proposals “had points of order against them and we never make amendments in order with points of order against them.”

Here are the descriptions of measures that the Rules Committee made in order for floor votes: 

Rep. Alexandria Ocasio-Cortez (D-NY): Allows United States researchers to study and examine the potential impacts of several schedule I drugs, such as MDMA, psilocybin, and or ibogaine, that have been shown to be effective in treating critical diseases.

Rep. Kurt Schrader (D-OR): Increases and decreases by $5 million, funding for the Center for Food Safety and Applied Nutrition at the FDA, to highlight the need for the Agency to proceed with rulemaking on cannabidiol (or CBD) by no later than 180 days after enactment, out of concern that the FDA has not initiated rulemaking to establish a regulatory pathway for CBD as a dietary supplement and food ingredient.

Rep. Debbie Lesko (R-AZ): Strikes language that allows federal funding to go to institutions of higher education that are conducting research on marijuana.

Rep. Doug LaMalfa (R-CA): Transfers $25 million from the Environmental Programs and Management enforcement activities account to the National Forest System account for enforcement and remediation of illegal marijuana trespass grow sites on federal lands and for the clean-up of toxic waste and chemicals at these sites.

Here are the amendments that were not ruled in order and are thus dead: 

Rep. Eleanor Holmes Norton (D-DC): Prohibits HUD from enforcing the prohibition on the use or possession of marijuana in federally assisted housing in states where marijuana is legal.

Rep. Eleanor Holmes Norton (D-DC): Prohibits HUD from enforcing the prohibition on the use or possession of medical marijuana in federally assisted housing in states where medical marijuana is legal.

Rep. Doug LaMalfa (R-CA): Prohibits funds from this section from being used to fund needle distribution programs for illegal drugs.

Rep. Ted Butt (R-NC): Prohibits federal funds from being used to purchase clean syringes for illegal drug use.

Rep. Ted Butt (R-NC): Prohibits federal funds from being used to purchase clean syringes for illegal drug use in DC.

Rep. French Hill (R-AR): Increases funding by $50 million for the Office of National Drug Control Policy’s High Intensity Drug Trafficking Areas Program. Offsets the increase with a decrease in funding of $50 million for the Electric Vehicles Fund.


Marijuana Moment is already tracking more than 1,100 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

Overall, these amendments were targeted for inclusion in an appropriations “minibus” bill for fiscal year 2022 to fund the Departments of Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development.

The spending package that is now heading to the House floor for votes on Tuesday also, under its language as originally introduced in appropriations subcommittees, would allow Washington, D.C. to use its local tax dollars to implement a system of lawful marijuana sales for adults.

That stands in contrast to a budget proposal from President Joe Biden, whose administration is seeking to keep language protecting medical cannabis states from federal intervention but has excluded the provision on giving D.C. autonomy to legalize marijuana commerce.

Another provision that was added as part of the Financial Services and General Government (FSGG) spending bill would protect banks that work with marijuana businesses. Further, the committee report attached to that legislation encourages federal government agencies to reconsider policies that fire employees for using marijuana in compliance with state law.

Federal health agencies should pursue research into the therapeutic potential of psychedelics for military veterans suffering from a host of mental health conditions, a report attached to separate spending legislation that’s part of the advancing minibus package says.

Report language also directs the U.S. Department of Veterans Affairs (VA) to improve communication on veteran eligibility for home loans and report back to Congress on its progress within 180 days of the enactment of the legislation. A separate provision urges VA to expand research on the medical benefits of cannabis for veterans.

In the report for Agriculture Department funding, lawmakers took issue with the 2018 Farm Bill’s 0.3 percent THC cap for lawful hemp products and directed USDA to work with the U.S. Department of Health and Human Services (HHS) and DEA on a study of whether that threshold is scientifically backed. That report also addressed numerous other issues related to the crop.

Other report language attached to this spending package highlights the difficulty of studying Schedule I drugs like marijuana, recognizes the medical potential of cannabinoids like CBD, encourages federal agencies not to restrict the plant kratom and acknowledges the lifesaving value of syringe access programs and safe consumption sites for illegal drugs.

The appropriations process this session has seen numerous drug policy reform provisions included in bill text and attached reports—also stopping immigrants from being deported for cannabis, for example, among other issues.

A bipartisan group of congressional lawmakers recently circulated a letter to build support for an amendment to a separate Department of Justice spending bill that would protect all state and tribal marijuana programs from federal interference—going beyond the existing measure that shields only medical cannabis states that’s currently enacted into law. There are now 15 cosponsors signed on to the broader proposal, which is expected to be considered by the Rules Committee and then potentially see floor action this week.

The Commerce, Justice, Science, and Related Agencies (CJS) spending report also notes that the Drug Enforcement Administration (DEA) has moved to approve additional marijuana manufacturers for research purposes and says the committee supports ongoing research efforts on cannabis, particularly in the wake of an outbreak of lung injuries associated with unregulated vaping products.

A provision was also attached to the bill that would make states and localities ineligible for certain federal law enforcement grants if they maintain a policy allowing for no-knock warrants for drug-related cases. That policy garnered national attention following the police killing of Breonna Taylor, who was fatally shot by law enforcement during a botched drug raid.

The Rules Committee is set to take up CJS and other appropriations legislation on Tuesday.

White House Declines To Blame Marijuana Sales For Violent Crime Spike Despite D.C. Police Chief’s Comments

Photo courtesy of Mike Latimer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

White House Declines To Blame Marijuana Sales For Violent Crime Spike Despite D.C. Police Chief’s Comments

Published

on

The White House on Monday declined the chance to blame illicit marijuana sales for a rise in violent crime in Washington, D.C.—despite the city’s police chief recently arguing that the issues are connected.

D.C. Police Chief Robert Contee suggested on Friday that part of the reason for the uptick in violent crime is connected to the illegal cannabis market, which he says has been deprioritized amid the national reform movement.

“When you have something where people get high reward—they can make a lot of money by selling illegal marijuana—and the risk is low, the risk for accountability is very low, that creates a very, very, very, very, very bad situation,” Contee argued at a press conference near the site of a shooting this month.

Advocates assert that Congress bears some blame for consistently passing a spending bill rider that bars the District from regulating retail sales after voters approved a 2014 initiative to legalize personal possession and cultivation for adults, thus relegating cannabis commerce to the illegal market.

Late last month, a House committee approved a large-scale funding bill that would allow the District to legalize cannabis sales by deleting the rider. The legislation is expected to pass the full House this week.

In any case, White House Press Secretary Jen Psaki was asked directly on Monday by a Fox News reporter whether the Biden administration thinks “that it may be time to get tougher on marijuana” in light of the chief’s comments. And she notably did not jump at the chance to vilify cannabis despite President Joe Biden’s ongoing opposition to adult-use legalization.

“We look to the crime that has been happening in D.C.—again one of the cities where we’ve seen rising violence over the past year and a half,” she said, pivoting quickly away from the cannabis query to discuss crime more generally. It’s “one we’re working in close partnership through both the [Justice Department] as well as our community violence intervention collaborative. We’re looking to address a range of causes, working in close partnership with the mayor and local police to bring crime down in our city.”

The fact that Psaki decided not to take aim at marijuana specifically, despite being prompted by comments made by one of the the top law enforcement official in the nation’s capital, is significant—if only because the administration to this point has been firmly footed in maintaining the status quo of prohibition.

Biden’s budget proposal specifically proposes continuing the longstanding Republican-led rider that has prevented the city from spending its own money to regulate adult-use cannabis commerce, for example.

Rep. Eleanor Holmes Norton (D-DC) in May blasted the president in an interview with Marijuana Moment for seeking to extend the provision blocking her city from making its own cannabis decisions, saying she is “going to be working very hard to make sure that that rider is not in the budget” that lawmakers ultimately send back to Biden’s desk.

Mayor Muriel Bowser (D) said in April that local officials are prepared to move forward with implementing a legal system of recreational cannabis sales in the nation’s capital just as soon as they can get over the final “hurdle” of congressional interference.

From advocates’ perspective, allowing D.C. to do what a growing number of states have already done by regulating cannabis could help mitigate the risks associated with enabling an illicit market to continue. Giving adults the option to purchase marijuana from a licensed retailer would make it less likely that the city would see any violent criminal activity that can be tied to illegal cannabis sales, they say.

Psaki didn’t make that point, but she didn’t seize the opportunity to target cannabis as a contributing factor to D.C. violence either.

This adds to the White House narrative on marijuana that’s evolved throughout the Biden administration.

During his presidential campaign last year, Biden ran on a pledge to enact other modest reforms such as decriminalizing cannabis possession, expunging prior records and respecting the rights of states to set their own laws. Since taking office, however, his administration has not made progress on any of those promises and has instead fired its own White House staffers over marijuana and is seeking to extend the D.C. sales block.

Biden took some by surprise by suggesting that international sports rules on marijuana may need to be reevaluated after star U.S. runner Sha’Carri Richardson was suspended following a positive cannabis test. But that’s a far cry from endorsing comprehensive reform.

Psaki, for her part, initially declined to condemn Olympics officials’ sanction on Richardson when asked about the issue at an earlier briefing with reporters. But she later told CNN that the case highlights the need to “take another look” at the rules on cannabis.

In April, the press secretary said that Biden’s campaign pledge to release federal inmates with marijuana convictions will start with modestly rescheduling cannabis—a proposal that advocates say wouldn’t actually accomplish what she’s suggesting.

On broad legalization, Psaki said recently that the president remains opposed to the reform, despite Senate leadership introducing a bill this month to federally legalize marijuana.

Sen. Cory Booker (D-NJ), one of the three leaders on the measure, said recently that he and his Senate colleagues will be talking to the White House now that they’ve released draft reform legislation.

FDA Seeks Public Input On Possible Global Kratom Ban After Domestic Scheduling Effort Stalled

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

FDA Seeks Public Input On Possible Global Kratom Ban After Domestic Scheduling Effort Stalled

Published

on

After failing to get kratom prohibited domestically, the Food and Drug Administration (FDA) is now seeking public comment to inform the U.S. position on how the substance should be scheduled under international statute.

In a notice published in the Federal Register last week, the agency is soliciting feedback on a number of substances. But advocates are especially concerned about where FDA and global drug officials come down on kratom, which has been touted as a natural painkiller that works as a safer alternative to prescription opioids.

The U.S. agency doesn’t quite see it that way, however.

“Kratom is abused for its ability to produce opioid-like effects,” FDA wrote in the notice. “Kratom is available in several different forms to include dried/crushed leaves, powder, capsules, tablets, liquids, and gum/ resin. Kratom is an increasingly popular drug of abuse and readily available on the recreational drug market in the United States.”

Responses to the notice will help inform the federal government’s stance on kratom scheduling in advance of an October meeting of the World Health Organization’s (WHO) Expert Committee on Drug Dependence, where international officials will discuss whether to recommend the substance be globally scheduled.

“The FDA’s request for public comments on a matter of such importance involving the international scheduling of kratom is an extraordinary abuse of their authority,” Mac Haddow, senior fellow of public policy at the American Kratom Association (AKA), told Marijuana Moment.

He said the August 9 deadline for the responses allows “only three weeks for scientists, public policy makers and consumers to provide responses that are well researched and responsive to the complex requirements for data and information that will be considered by the WHO Expert Committee” and is therefore “unacceptable.”

As it stands, kratom is not scheduled under the federal Controlled Substances Act or under international drug treaties to which the U.S. is a party. But some advocates suspect that since FDA has been unable so far to impose a ban on kratom domestically, it may use the WHO convention as an opportunity to get prohibition enacted internationally, a move that the country would be compelled to comply with.

“If that happens, there are 37 countries that are part of that international treaty that will effectively ban kratom around the world,” Haddow said in a recent video update to supporters. “The FDA cannot get kratom scheduled here in the United States using the criteria that’s established by the Controlled Substances Act, so they’re circumventing that and going to the WHO.”

Haddow encouraged people to take advantage of the public comment period—but to remember that WHO is the target audience for those comment, not FDA.

“We want thousands of people to comment because every one of those comments will have to be packaged up and sent to the World Health Organization,” he said. “We don’t want people complaining about the FDA overreach because we can fight that battle on a separate battleground, but we want the WHO to know the powerful experiences that people have had” with kratom.

FDA, in its Federal Register notice, said the comments “will be considered in preparing a response from the United States to the World Health Organization (WHO) regarding the abuse liability and diversion of these drugs.”

Haddow told Marijuana Moment that the federal agency “is prosecuting a war on kratom to criminalize more than 15 million Americans, and they ignore the public health impacts of kratom consumers being forced to opioids with a high potential for addiction and that can be deadly.”

“More overdose deaths will occur if kratom is banned, and that is exactly what the FDA is trying to do,” he said.

On the domestic level, the House Appropriations Committee recently approved a report to spending legislation that says federal health agencies have “contributed to the continued understanding of the health impacts of kratom, including its constituent compounds, mitragynine and 7-hydroxymitragynine.”

“The Committee is aware of the potential promising results of kratom for acute and chronic pain patients who seek safer alternatives to sometimes dangerously addictive and potentially deadly prescription opioids and of research investigating the use of kratom’s constituent compounds for opioid use disorder,” it said.

It also directed the Health and Human Services secretary to continue to refrain from recommending that kratom be controlled in Schedule I.

Late last year, the Agency for Healthcare Research and Quality (AHRQ) asked the public to help identify research that specifically looks at the risks and benefits of cannabinoids and kratom.

The Centers for Disease Control and Prevention (CDC) last year separately received more than one thousand comments concerning kratom as part of another public solicitation.

FDA has on several occasions solicited public input to shape the government’s position on the international scheduling of marijuana and cannabinoids. The agency initially requested feedback on the proposal in March 2019 and then reopened that comment period five months later.

Last year, the United Nations approved a U.S.-backed WHO recommendation to remove marijuana from the most restrictive global scheduling category. However, the U.S. opposed several other cannabis reform proposals, including the one to clarify that CBD is not under international control.

D.C. Police Chief Says Illicit Marijuana Sales Tied To Violence As Congress Weighs Lifting Regulatory Blockade

Photo courtesy of Wikimedia/ThorPorre.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment